Immutep Provides Data from the P-IIb (TACTI-003) Study of Eftilagimod Alfa to Treat Head and Neck Squamous Cell Carcinoma
Shots:
- Immutep reported results from cohort B of P-IIb (TACTI-003) trial assessing eftilagimod alfa + Keyruda vs Keytruda alone as a 1L treatment in recurrent or metastatic HNSCC patients with PD-L1+ve tumors (cohort A) and eftilagimod alfa + Keytruda in patients with PD-L1-ve tumors (cohort B)
- The study showed an ORR of 35.5% (11/31 evaluable patients), DCR of 58.1% & CRR of 9.7% (3/31 patients) with 1 patient having early progressive disease achieving a confirmed PR remained on therapy for 14mos., resulting in an ORR of 38.7%; safety profile was favorable without any new concerns
- The company will discuss the next steps with the regulatory authorities based on these outcomes
Ref: Immutep | Image: Immutep
Related News:- Immutep Partners with Merck to Conduct P-III Study of Eftilagimod Alfa (Efti) with Keytruda for Treating NSCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
